يعرض 81 - 100 نتائج من 3,237 نتيجة بحث عن '(( significantly small decrease ) OR ( significantly ((alter decrease) OR (teer decrease)) ))', وقت الاستعلام: 0.61s تنقيح النتائج
  1. 81
  2. 82
  3. 83
  4. 84
  5. 85
  6. 86
  7. 87
  8. 88
  9. 89
  10. 90

    Electroretinogram (ERG) recordings from 6-, 9-, and 12-month mice show deficits in 5xFAD photoreceptors. حسب Shaylah McCool (20818280)

    منشور في 2025
    "…<p>(A) Example ERG traces from C57 (black) and 5xFAD (blue) mice at 3 timepoints show waveforms produced by 9 stimulus intensities ranging from 0.0005–3.0000 cd * s/m<sup>2</sup>. (B) Significantly altered A- and B-wave amplitudes are seen in the 6- and 9-month 5xFAD mice. …"
  11. 91
  12. 92
  13. 93
  14. 94
  15. 95
  16. 96
  17. 97

    Table 4_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

    منشور في 2024
    "…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"
  18. 98

    Table 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

    منشور في 2024
    "…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"
  19. 99

    Table 5_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

    منشور في 2024
    "…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"
  20. 100

    Table 2_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... حسب Zachary D. Wallen (19986522)

    منشور في 2024
    "…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …"